C3N-02153
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 55.41683778
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.470
- OXIDATIVE_PHOSPHORYLATION+0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.420
- UNFOLDED_PROTEIN_RESPONSE+0.370
- ADIPOGENESIS+0.310
- PEROXISOME+0.280
- FATTY_ACID_METABOLISM+0.270
- PANCREAS_BETA_CELLS+0.260
- CHOLESTEROL_HOMEOSTASIS+0.250
- DNA_REPAIR+0.250
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- G2M_CHECKPOINT-0.350
- INFLAMMATORY_RESPONSE-0.350
- INTERFERON_GAMMA_RESPONSE-0.350
- E2F_TARGETS-0.330
- COMPLEMENT-0.300
- IL2_STAT5_SIGNALING-0.290
- IL6_JAK_STAT3_SIGNALING-0.290
- TNFA_SIGNALING_VIA_NFKB-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ULC1533T_S61 | — | cohortA2 | 0.875 |
| 2 | TCGA-D8-A1JS-01A-11R-A13Q-07 | — | B | 0.865 |
| 3 | SRR8943024 | — | — | 0.859 |
| 4 | MNG1094 | — | — | 0.855 |
| 5 | TCGA-BH-A18S-01A-11R-A12D-07 | — | B | 0.849 |
| 6 | SRR1072797 | GTEX | — | 0.832 |
| 7 | X265fd2ee.a8d9.4142.bf96.86a40f37234e | — | cohortA2 | 0.827 |
| 8 | TCGA-TN-A7HJ-01A-12R-A34R-07 | — | — | 0.826 |
| 9 | C3L-02961 | — | cohortA2 | 0.824 |
| 10 | SRR8518211 | — | C | 0.821 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.470 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.430 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.420 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.370 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.310 | Inavolisib | — uncovered |
| PEROXISOME | 0.280 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.250 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.240 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.060 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.060 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.020 | Inavolisib | — uncovered |